The FDA has granted Virtuoso Surgical De Novo authorization for a robotic endoscopy system that removes bladder tumors in one intact piece, the company announced on November 10, 2026. The clearance creates a new device classification for electromechanical surgical systems used in endoluminal procedures, meaning Virtuoso's system becomes the regulatory benchmark future competitors will be measured against, rather than the reverse.
The system threads a standard-sized endoscope through the urethra, with two miniaturized robotic arms built into its tip. A surgeon controls the arms to cut around a bladder lesion and lift it out whole, along with a sample of the underlying detrusor muscle, without a single incision. The FDA's authorization specifically covers using the device to obtain tissue, including detrusor muscle, for diagnostic evaluation of bladder cancer.
Why removing tumors whole matters
Standard transurethral resection, the decades-old technique most bladder tumors are removed with today, typically shaves a lesion into fragments. That approach works, but it can leave pathologists without a clear picture of how deep a tumor has grown into the bladder wall, a detail that often decides whether a patient needs more aggressive treatment such as chemotherapy or bladder removal. Virtuoso's en bloc technique, which removes the lesion in one piece or in larger segments, is designed to preserve that structural information for diagnosis.
Clinical support for the authorization came from the Virtuoso Improving Anatomic Bladder Lesion Excision trial, a prospective study that tracked the system's safety and effectiveness in transurethral bladder lesion excision. The company first secured FDA breakthrough device designation for the technology, a status reserved for devices that offer more effective treatment or diagnosis of life-threatening conditions, before advancing to this week's clearance.
A fresh lane inside a crowded robotic surgery market
Surgical robotics has largely been defined by Intuitive Surgical's da Vinci platform, which dominates general and urologic procedures performed through small abdominal incisions. Virtuoso is carving out different territory: miniaturized robotic arms small enough to travel through natural body openings like the urethra, a category sometimes called endoluminal robotics. By creating its own FDA device classification rather than seeking clearance as equivalent to an existing product, Virtuoso has effectively written the rules for that category going forward.
Bladder cancer is diagnosed in hundreds of thousands of patients worldwide each year, and the initial resection procedure doubles as both treatment and the primary tool doctors use to stage the disease. A device that improves the reliability of that staging step has implications well beyond the operating room, since downstream treatment decisions depend heavily on what pathologists find in the removed tissue.
What happens next
Virtuoso says it plans to bring the system to leading urology centers starting in 2027, giving hospitals roughly a year to evaluate the technology before wider rollout. The De Novo pathway also lowers the bar for future entrants in endoluminal robotics, since later devices can seek clearance by showing they are substantially equivalent to Virtuoso's system rather than building a case from scratch. That could accelerate competition in a corner of surgical robotics that has drawn far less attention than abdominal and thoracic platforms. For now, Virtuoso holds a rare position: the company that didn't just win a clearance, but defined the category it now leads. See Urology Times for more on the authorization.